Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 9/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354681 | 0.98 | SMPD1 (0.42) | SMPD1GGPS1S1PR2S1PR4S1PR1 | |
| SCHEMBL6356292 | 0.91 | SMPD1 (0.38) | SMPD1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL13095381 | 0.88 | SMPD1 (0.53) | SMPD1GGPS1S1PR2S1PR4S1PR1 | |
| SCHEMBL6518662 | 0.87 | SMPD1 (0.38) | SMPD1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL6346290 | 0.84 | SMPD1 (0.35) | SMPD1FDPSGRM4 | |
| SCHEMBL6346076 | 0.82 | SMPD1 (0.36) | SMPD1GRM4 | |
| SCHEMBL14671500 | 0.81 | SMPD1 (0.67) | SMPD1GGPS1FDPSLPAR1LPAR3 | |
| SCHEMBL9660425 | 0.81 | SMPD1 (0.67) | SMPD1GGPS1FDPSLPAR1LPAR3 | |
| SCHEMBL13896287 | 0.81 | SMPD1 (0.67) | SMPD1GGPS1FDPSLPAR1LPAR3 | |
| SCHEMBL28466128 | 0.81 | SMPD1 (0.67) | SMPD1GGPS1FDPSLPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004532799-A | — | — | 2004-10-28 | — | — | JP | claimed |
| US-6703422-B2 | FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISEASE, DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; DISORDER OF GLUCOSE METABOLISM; ALZHEIMER'S DISEASE; SYNDROME X; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ASSOCIATED DISORDER | ESPERION THERAPEUTICS, INC. | 2004-03-09 | — | — | US | claimed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, IAPP, STS | SMPD1 221/4885GGPS1 305/4885S1PR2 818/4885 |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | SMPD1 278/4885GGPS1 284/4885S1PR2 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.